Page 1 | Search Results | Diabetes | American Diabetes Association

1-16 of 16

Sort by

Sort Order Select

Meeting Abstracts

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, WEICHUNG J. SHIH, MARIO MALDONADO, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, URSZULA MASIUKIEWICZ, CHRISTOPHER P. CANNON

Diabetes 2021;70(Supplement_1):796-P

https://doi.org/10.2337/db21-796-P

Published: 01 June 2021

View articletitled, 796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

Meeting Abstracts

791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

RICHARD E. PRATLEY, SAMUEL DAGOGO-JACK, BERNARD CHARBONNEL, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, MARGARET N. ESSEX, PHILIP L.S. JONES, JIE LIU, INGRID A. ADAMSONS, DAVID LAWRENCE, WEICHUNG J. SHIH, CHRISTOPHER P. CANNON

Diabetes 2021;70(Supplement_1):791-P

https://doi.org/10.2337/db21-791-P

Published: 01 June 2021

View articletitled, 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

Meeting Abstracts

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, CHRISTOPHER P. CANNON, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, WEICHUNG J. SHIH, JIE LIU, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):783-P

https://doi.org/10.2337/db21-783-P

Published: 01 June 2021

View articletitled, 783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

Meeting Abstracts

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

SAMUEL DAGOGO-JACK, ROBERT FREDERICH, BERNARD CHARBONNEL, JIE LIU, CHRISTOPHER P. CANNON, HARRY SHI, DARREN K. MCGUIRE, DAVID CHERNEY, FRANCESCO COSENTINO, WEICHUNG J. SHIH, URSZULA MASIUKIEWICZ, IRA GANTZ, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):785-P

https://doi.org/10.2337/db21-785-P

Published: 01 June 2021

View articletitled, 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

Meeting Abstracts

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, DAVID CHERNEY, BERNARD CHARBONNEL, DARREN K. MCGUIRE, FRANCESCO COSENTINO, WEICHUNG J. SHIH, JIE LIU, ROBERT FREDERICH, JAMES P. MANCUSO, ANNASWAMY RAJI, IRA GANTZ

Diabetes 2021;70(Supplement_1):786-P

https://doi.org/10.2337/db21-786-P

Published: 01 June 2021

View articletitled, 786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

Meeting Abstracts

1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

KAMLESH KHUNTI, BERNARD CHARBONNEL, ANDREW COOPER, MARILIA B. GOMES, LINONG JI, PAUL LEIGH, ANTONIO NICOLUCCI, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, AFRAH SIDDIQUI, FENGMING TANG, HIROTAKA WATADA, HUNGTA CHEN

Diabetes 2020;69(Supplement_1):1590-P

https://doi.org/10.2337/db20-1590-P

Published: 01 June 2020

View articletitled, 1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

Meeting Abstracts

1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

Diabetes 2019;68(Supplement_1):1448-P

https://doi.org/10.2337/db19-1448-P

Published: 01 June 2019

View articletitled, 1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

Meeting Abstracts

1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly

RICHARD E. PRATLEY, SAMUEL DAGOGO-JACK, BERNARD CHARBONNEL, SHRITA M. PATEL, MARY A. HICKMAN, JIE LIU, LISA TARASENKO, MISOO C. ELLISON, IRA GANTZ, STEVEN G. TERRA

Diabetes 2019;68(Supplement_1):1210-P

https://doi.org/10.2337/db19-1210-P

Published: 01 June 2019

View articletitled, 1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly

Meeting Abstracts

1628-P: Changes in HbA_1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

BERNARD CHARBONNEL, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, MARILIA B. GOMES, GABRIELA LUPORINI SARAIVA, JESUS MEDINA, ANTONIO NICOLUCCI, STUART POCOCK, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, SHAUKAT M. SADIKOT, FILIP SURMONT, FENGMING TANG, JITEN VORA, HIROTAKA WATADA, KAMLESH KHUNTI

Diabetes 2019;68(Supplement_1):1628-P

https://doi.org/10.2337/db19-1628-P

Published: 01 June 2019

View articletitled, 1628-P: Changes in HbA1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

Meeting Abstracts

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

BERNARD CHARBONNEL, VANITA R. ARODA, JUKKA WESTERBACKA, FELIPE LAUAND, SR., EMMANUELLE BOELLE, ALICE Y. CHENG, JULIO ROSENSTOCK, GEREMIA B. BOLLI

Diabetes 2019;68(Supplement_1):131-LB

https://doi.org/10.2337/db19-131-LB

Published: 01 June 2019

View articletitled, 131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

Meeting Abstracts

207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study

Diabetes 2019;68(Supplement_1):207-LB

https://doi.org/10.2337/db19-207-LB

Published: 01 June 2019

View articletitled, 207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study

Meeting Abstracts

Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER

BERNARD CHARBONNEL, FABRICE BONNET, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, MARILIA B. GOMES, NIKLAS HAMMAR, LINONG JI, KEVIN KENNEDY, MIKHAIL KOSIBOROD, STUART POCOCK, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, FILIP SURMONT, KAMLESH KHUNTI

Diabetes 2018;67(Supplement_1):1615-P

https://doi.org/10.2337/db18-1615-P

Published: 01 July 2018

View articletitled, Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER

Meeting Abstracts

Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

SILVINA GALLO, BERNARD CHARBONNEL, ALLISON GOLDMAN, HARRY SHI, SUSAN HUYCK, AMANDA DAREKAR, BRETT LAURING, STEVEN TERRA

Diabetes 2018;67(Supplement_1):1129-P

https://doi.org/10.2337/db18-1129-P

Published: 01 July 2018

View articletitled, Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

Journal Articles

In Vitro Relationship of CD4 Cells From Type I Diabetic Patients and Xenogeneic β-Cell Membranes

Jean-Pierre Segain, Alexis Valentin, Stephane Bardet, Bruno Feve, Helene Sevestre, Elisabeth Houssaint, Bernard Charbonnel, Pierre Sai

Diabetes 1989;38(5):634–640

https://doi.org/10.2337/diab.38.5.634

Published: 01 May 1989

View articletitled, In Vitro Relationship of CD4 Cells From Type I Diabetic Patients and Xenogeneic β-Cell Membranes

Journal Articles

Cytoadherence of Lymphocytes From Type I Diabetic Subjects to Insulin-Secreting Cells: Marker of Anti-β-Cell Cellular Immunity

François Lang, Didier Maugendre, Elisabeth Houssaint, Bernard Charbonnel, Pierre Sai

Diabetes 1987;36(12):1356–1364

https://doi.org/10.2337/diab.36.12.1356

Published: 01 December 1987

View articletitled, Cytoadherence of Lymphocytes From Type I Diabetic Subjects to Insulin-Secreting Cells: Marker of Anti-β-Cell Cellular Immunity

Journal Articles

Glucose Tolerance in Viral Hepatitis: A Study of Twenty Patients During the Acute Phase and After Recovery

Maurice Chupin, MD, Bernard Charbonnel, MD, Louis Le Bodic, MD, Jean-Yves Grolleau, MD, Françoise Chupin, Jean Guillon, MD

Diabetes 1978;27(6):661–669

https://doi.org/10.2337/diab.27.6.661

Published: 01 June 1978

View articletitled, Glucose Tolerance in Viral Hepatitis: A Study of Twenty Patients During the Acute Phase and After Recovery

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly

1628-P: Changes in HbA_1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study

Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER

Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

In Vitro Relationship of CD4 Cells From Type I Diabetic Patients and Xenogeneic β-Cell Membranes

Cytoadherence of Lymphocytes From Type I Diabetic Subjects to Insulin-Secreting Cells: Marker of Anti-β-Cell Cellular Immunity

Glucose Tolerance in Viral Hepatitis: A Study of Twenty Patients During the Acute Phase and After Recovery

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only